Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 3,860 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 3,860 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $36.22, for a total transaction of $139,809.20. Following the completion of the sale, the insider now directly owns 247,173 shares of the company's stock, valued at $8,952,606.06. This trade represents a 1.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, March 5th, Carl Dambkowski sold 1,590 shares of Apogee Therapeutics stock. The shares were sold at an average price of $30.48, for a total transaction of $48,463.20.
• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The shares were sold at an average price of $40.69, for a total transaction of $143,228.80.

Apogee Therapeutics Trading Up 0.6 %

Apogee Therapeutics stock traded up $0.17 during trading hours on Wednesday, reaching $28.96. 640,385 shares of the company were exchanged, compared to its average volume of 497,629. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -11.99 and a beta of 1.72. Apogee Therapeutics, Inc. has a 12 month low of $26.20 and a 12 month high of $63.50. The stock has a 50-day moving average of $36.60 and a 200 day moving average of $44.93.

Remove Ads

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). As a group, research analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on APGE shares. Citigroup started coverage on Apogee Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $95.00 price objective for the company. Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Wedbush reaffirmed an "outperform" rating and set a $90.00 price objective on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of "Buy" and an average price target of $92.17.

Institutional Trading of Apogee Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. GF Fund Management CO. LTD. acquired a new position in Apogee Therapeutics in the 4th quarter valued at approximately $43,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Apogee Therapeutics in the 3rd quarter valued at $71,000. Wexford Capital LP bought a new position in shares of Apogee Therapeutics during the 3rd quarter worth about $230,000. Optimize Financial Inc bought a new position in shares of Apogee Therapeutics during the 4th quarter worth about $203,000. Finally, Aigen Investment Management LP acquired a new stake in shares of Apogee Therapeutics during the 4th quarter valued at about $216,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.